![Stephen Man BSc, PhD](https://profiles-cardiff.imgix.net/attachments/8610?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwg
Ymddeolais fel Darllenydd yn yr Is-adran Canser a Geneteg (DCG), yn yr Ysgol Feddygaeth. Roedd fy ymchwil yn canolbwyntio ar rôl y system imiwnedd mewn canser. Rwy'n arbenigwr ar gelloedd T dynol ac am sawl blwyddyn, astudiais rôl y celloedd hyn mewn lewcemia. Mae fy ymchwil a ariennir gan Bloodwise ac Ymchwil Canser Cymru wedi nodi targedau newydd ar gyfer ymosodiad imiwnedd, ac wedi dangos bod gan gleifion â chlefyd mwy ymosodol boblogaethau celloedd T annormal. Ein nod oedd cyfieithu'r canfyddiadau hyn er budd cleifion.
Y tu allan i'r labordy, roeddwn i'n weithgar mewn ymgysylltu â'r gymuned (manylion o dan y tab Ymgysylltu) ac roeddwn yn gyd-sylfaenydd Rhwydwaith Staff Rhyngwladol Prifysgol Caerdydd. Mae'r rhwydwaith hwn yn sefydliad staff gwirfoddol sy'n darparu cyngor a chefnogaeth i staff rhyngwladol wrth iddynt drosglwyddo i fywyd yng Nghaerdydd a'r DU. Cawsom ein cydnabod gan "Wobr Dathlu Rhagoriaeth am Gyfraniad Gwirfoddol" Prifysgol Caerdydd yn 2019.
Cyhoeddiad
2023
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16), pp.3333-3349. E27. (10.1016/j.cell.2023.06.020)
2021
- Man, S. et al. 2021. Synthetic peptides with inadvertent chemical modifications can activate potentially autoreactive T cells. The Journal of Immunology 207 (4), pp.1009-1017. (10.4049/jimmunol.2000756)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
2020
- Elston, L. et al. 2020. Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL. British Journal of Haematology 188 (6), pp.872-880. (10.1111/bjh.16260)
2019
- Man, S. and Henley, P. 2019. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British Journal of Haematology 186 (2), pp.220-233. (10.1111/bjh.15918)
2018
- Pirotte, E. F. et al. 2018. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. PLoS ONE 13 (12), pp.-. e0207934. (10.1371/journal.pone.0207934)
2017
- Dockree, T. et al. 2017. CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold. Immunology and Cell Biology 95 (1), pp.68-76. (10.1038/icb.2016.85)
2016
- Parry, H. M. et al., 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91 (8), pp.776-781. (10.1002/ajh.24403)
- Sacco, J. J. et al., 2016. Systemic listeriosis following vaccination with the attenuatedListeria monocytogenestherapeutic vaccine, ADXS11-001. Human Vaccines & Immunotherapeutics 12 (4), pp.1085-1086. (10.1080/21645515.2015.1121338)
2015
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
- Reid, R. et al. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144 (3), pp.495-505. (10.1111/imm.12398)
2014
- Tristram, A. et al. 2014. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology 15 (12), pp.1361-1368. (10.1016/S1470-2045(14)70456-5)
- Stanton, R. J. et al. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host and Microbe 16 (2), pp.201-214. (10.1016/j.chom.2014.07.005)
2013
- Wong, R. F. et al. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98 (12), pp.1930-1938. (10.3324/haematol.2012.082248)
- Man, S. 2013. Back to the future: learning from cancer vaccine trials in Cardiff. Applied Immunohistochemistry and Molecular Morphology 21 (2), pp.110-115. (10.1097/PAI.0b013e3182811612)
- Al-Taei, S. et al. 2013. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunology, Immunotherapy 62 (12), pp.1821-1830. (10.1007/s00262-013-1488-5)
2012
- Nunes, C. T. et al. 2012. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 18 (3), pp.678-687. (10.1158/1078-0432.CCR-11-2630)
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
2011
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Chan, P. K. S. et al., 2011. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. Journal of Medical Virology 83 (6), pp.1023-1030. (10.1002/jmv.21889)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Nunes, C. T. et al. 2011. A novel tumor antigen derived from enhanced degradation of Bax protein in human cancers. Cancer Research 71 (16), pp.5435-5444. (10.1158/0008-5472.CAN-11-0393)
2010
- Campo, M. S. et al., 2010. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407 (1), pp.137-142. (10.1016/j.virol.2010.07.044)
- Chan, P. K. S. et al., 2010. T-Cell response to human papillomavirus type 58 L1, E6, and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clinical and Vaccine Immunology 17 (9), pp.1315-1321. (10.1128/CVI.00105-10)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
2008
- Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2.Springer. , pp.129-160. (10.1007/978-1-4020-8442-3)
- Thomas, K. J. et al., 2008. HPV16 E629-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. International Journal of Cancer 122 (12), pp.2791-2799. (10.1002/ijc.23475)
2007
- Capper, R. et al. 2007. The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes and Development 21 (19), pp.2495-2508. (10.1101/gad.439107)
2006
- McCarthy, C. , Youde, S. J. and Man, S. T. 2006. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. International Journal of Cancer 118 (10), pp.2514-21. (10.1002/ijc.21643)
- Fiander, A. N. et al. 2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. International Journal of Gynecological Cancer 16 (3), pp.1075-1081. (10.1111/j.1525-1438.2006.00598.x)
2005
- Youde, S. J. et al. 2005. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. International Journal of Cancer 114 (4), pp.606-12. (10.1002/ijc.20779)
- Hill, S. C. et al., 2005. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Journal of Immunology 174 (1), pp.41-50.
- Lyons, G. E. et al., 2005. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunology, Immunotherapy 55 (9), pp.1142-1150. (10.1007/s00262-005-0103-9)
- Smith, K. L. et al., 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. International Immunology 17 (2), pp.167-176. (10.1093/intimm/dxh197)
- Wall, S. R. et al., 2005. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. British Journal of Cancer 93 (9), pp.1068-1076. (10.1038/sj.bjc.6602736)
2004
- Man, S. T. et al. 2004. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103 (12), pp.4613-4615. (10.1182/blood-2003-11-3903)
- Smyth, L. J. C. et al., 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clinical Cancer Research 10 (9), pp.2954-2961. (10.1158/1078-0432.CCR-03-0703)
2003
- Adams, M. et al., 2003. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21 (7-8), pp.787-90. (10.1016/S0264-410X(02)00599-6)
- Fiander, A. N. and Man, S. T. 2003. Antiviral vaccination for treating intraepithelial neoplasia. In: Maclean, A. B. , Singer, A. and Critchley, H. eds. Lower Genital Tract Neoplasia. London: RCOG Press. , pp.192-209.
2002
- Palmowski, M. J. et al., 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. The Journal of Immunology 168 (9), pp.4391-4398. (10.4049/jimmunol.168.9.4391)
- Savage, P. et al., 2002. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer 98 (4), pp.561-566. (10.1002/ijc.10219)
- Savage, P. et al., 2002. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. British Journal of Cancer 86 (8), pp.1336-1342. (10.1038/sj.bjc.6600223)
2001
- Evans, M. et al. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. The Journal of Immunology 167 (9), pp.5420-5428.
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19 (17-19), pp.2549-2556. (10.1016/S0264-410X(00)00488-6)
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in cervical cancer. In: Mackiewicz, A. , Kurpisz, M. and Zeromski, J. eds. Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology Vol. 442.New York: Kluwer Academic/Plenum Publishers. , pp.419-427. (10.1007/978-1-4615-0685-0_61)
- Lawson, T. et al. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. International Immunology 13 (11), pp.1383-1390. (10.1093/intimm/13.11.1383)
- Lawson, T. et al. 2001. Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. International Immunology 13 (11), pp.1373-1381. (10.1093/intimm/13.11.1373)
- Man, S. T. 2001. Recognition of human tumours: viral antigens as immunological targets for cytotoxic T cells. In: Robbins, R. A. and Rees, R. eds. Cancer Immunology. Immunology and Medicine Vol. 30.Springer. , pp.123-145.
- Man, S. T. and Fiander, A. N. 2001. Immunology of human papillomavirus infection in lower genital tract neoplasia [review]. Best Practice & Research Clinical Obstetrics & Gynaecology 15 (5), pp.701-714. (10.1053/beog.2001.0215)
2000
- Borysiewicz., L. K. and Man, S. T. 2000. Vaccinia-based human papillomavirus vaccines in cervical cancer. In: Stern, P. L. , Beverley, P. C. L. and Carroll, M. W. eds. Cancer vaccines and immunotherapy. Cambridge, UK: Cambridge University Press. , pp.62-81.
- Evans, M. , Man, S. T. and Borysiewicz, L. K. 2000. Vaccine strategies for cancer. In: Weissberg, P. ed. Horizons in Medicine. Vol. 12, London: Royal College of Physicians. , pp.289-300.
- Youde, S. J. et al. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Research 60 (2), pp.365-371.
1999
- Man, S. T. et al. 1999. Recombinant vaccinia virus. In: Tindle, R. W. ed. Vaccines for Human Papillomavirus Infection and anogenital disease, 14th ed.. Medical Intelligence Unit Austin, Texas: R.G. Landes Company. , pp.69-90.
1997
- Nimako, M. et al., 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Research 57 (21), pp.4855-4861.
- Fiander, A. N. et al. 1997. Therapeutic vaccines for cervical cancer: concept and clinical results. Biodrugs -Auckland- 8 (5), pp.331-338. (10.2165/00063030-199708050-00001)
1996
- Borysiewicz, L. K. et al., 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. The Lancet 347 (9014), pp.1523-1527. (10.1016/s0140-6736(96)90674-1)
1995
- Borysiewicz, L. K. et al., 1995. Development and initial clinical studies of TA-HPV in cervical cancer. European Journal of Cancer 31 (supp 3), pp.17-17. (10.1016/0959-8049(95)99882-z)
Adrannau llyfrau
- Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2.Springer. , pp.129-160. (10.1007/978-1-4020-8442-3)
- Fiander, A. N. and Man, S. T. 2003. Antiviral vaccination for treating intraepithelial neoplasia. In: Maclean, A. B. , Singer, A. and Critchley, H. eds. Lower Genital Tract Neoplasia. London: RCOG Press. , pp.192-209.
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in cervical cancer. In: Mackiewicz, A. , Kurpisz, M. and Zeromski, J. eds. Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology Vol. 442.New York: Kluwer Academic/Plenum Publishers. , pp.419-427. (10.1007/978-1-4615-0685-0_61)
- Man, S. T. 2001. Recognition of human tumours: viral antigens as immunological targets for cytotoxic T cells. In: Robbins, R. A. and Rees, R. eds. Cancer Immunology. Immunology and Medicine Vol. 30.Springer. , pp.123-145.
- Borysiewicz., L. K. and Man, S. T. 2000. Vaccinia-based human papillomavirus vaccines in cervical cancer. In: Stern, P. L. , Beverley, P. C. L. and Carroll, M. W. eds. Cancer vaccines and immunotherapy. Cambridge, UK: Cambridge University Press. , pp.62-81.
- Evans, M. , Man, S. T. and Borysiewicz, L. K. 2000. Vaccine strategies for cancer. In: Weissberg, P. ed. Horizons in Medicine. Vol. 12, London: Royal College of Physicians. , pp.289-300.
- Man, S. T. et al. 1999. Recombinant vaccinia virus. In: Tindle, R. W. ed. Vaccines for Human Papillomavirus Infection and anogenital disease, 14th ed.. Medical Intelligence Unit Austin, Texas: R.G. Landes Company. , pp.69-90.
Erthyglau
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16), pp.3333-3349. E27. (10.1016/j.cell.2023.06.020)
- Man, S. et al. 2021. Synthetic peptides with inadvertent chemical modifications can activate potentially autoreactive T cells. The Journal of Immunology 207 (4), pp.1009-1017. (10.4049/jimmunol.2000756)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
- Elston, L. et al. 2020. Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL. British Journal of Haematology 188 (6), pp.872-880. (10.1111/bjh.16260)
- Man, S. and Henley, P. 2019. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British Journal of Haematology 186 (2), pp.220-233. (10.1111/bjh.15918)
- Pirotte, E. F. et al. 2018. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. PLoS ONE 13 (12), pp.-. e0207934. (10.1371/journal.pone.0207934)
- Dockree, T. et al. 2017. CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold. Immunology and Cell Biology 95 (1), pp.68-76. (10.1038/icb.2016.85)
- Parry, H. M. et al., 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91 (8), pp.776-781. (10.1002/ajh.24403)
- Sacco, J. J. et al., 2016. Systemic listeriosis following vaccination with the attenuatedListeria monocytogenestherapeutic vaccine, ADXS11-001. Human Vaccines & Immunotherapeutics 12 (4), pp.1085-1086. (10.1080/21645515.2015.1121338)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
- Reid, R. et al. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144 (3), pp.495-505. (10.1111/imm.12398)
- Tristram, A. et al. 2014. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology 15 (12), pp.1361-1368. (10.1016/S1470-2045(14)70456-5)
- Stanton, R. J. et al. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host and Microbe 16 (2), pp.201-214. (10.1016/j.chom.2014.07.005)
- Wong, R. F. et al. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98 (12), pp.1930-1938. (10.3324/haematol.2012.082248)
- Man, S. 2013. Back to the future: learning from cancer vaccine trials in Cardiff. Applied Immunohistochemistry and Molecular Morphology 21 (2), pp.110-115. (10.1097/PAI.0b013e3182811612)
- Al-Taei, S. et al. 2013. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunology, Immunotherapy 62 (12), pp.1821-1830. (10.1007/s00262-013-1488-5)
- Nunes, C. T. et al. 2012. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 18 (3), pp.678-687. (10.1158/1078-0432.CCR-11-2630)
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Chan, P. K. S. et al., 2011. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. Journal of Medical Virology 83 (6), pp.1023-1030. (10.1002/jmv.21889)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Nunes, C. T. et al. 2011. A novel tumor antigen derived from enhanced degradation of Bax protein in human cancers. Cancer Research 71 (16), pp.5435-5444. (10.1158/0008-5472.CAN-11-0393)
- Campo, M. S. et al., 2010. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407 (1), pp.137-142. (10.1016/j.virol.2010.07.044)
- Chan, P. K. S. et al., 2010. T-Cell response to human papillomavirus type 58 L1, E6, and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clinical and Vaccine Immunology 17 (9), pp.1315-1321. (10.1128/CVI.00105-10)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
- Thomas, K. J. et al., 2008. HPV16 E629-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. International Journal of Cancer 122 (12), pp.2791-2799. (10.1002/ijc.23475)
- Capper, R. et al. 2007. The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes and Development 21 (19), pp.2495-2508. (10.1101/gad.439107)
- McCarthy, C. , Youde, S. J. and Man, S. T. 2006. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. International Journal of Cancer 118 (10), pp.2514-21. (10.1002/ijc.21643)
- Fiander, A. N. et al. 2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. International Journal of Gynecological Cancer 16 (3), pp.1075-1081. (10.1111/j.1525-1438.2006.00598.x)
- Youde, S. J. et al. 2005. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. International Journal of Cancer 114 (4), pp.606-12. (10.1002/ijc.20779)
- Hill, S. C. et al., 2005. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Journal of Immunology 174 (1), pp.41-50.
- Lyons, G. E. et al., 2005. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunology, Immunotherapy 55 (9), pp.1142-1150. (10.1007/s00262-005-0103-9)
- Smith, K. L. et al., 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. International Immunology 17 (2), pp.167-176. (10.1093/intimm/dxh197)
- Wall, S. R. et al., 2005. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. British Journal of Cancer 93 (9), pp.1068-1076. (10.1038/sj.bjc.6602736)
- Man, S. T. et al. 2004. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103 (12), pp.4613-4615. (10.1182/blood-2003-11-3903)
- Smyth, L. J. C. et al., 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clinical Cancer Research 10 (9), pp.2954-2961. (10.1158/1078-0432.CCR-03-0703)
- Adams, M. et al., 2003. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21 (7-8), pp.787-90. (10.1016/S0264-410X(02)00599-6)
- Palmowski, M. J. et al., 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. The Journal of Immunology 168 (9), pp.4391-4398. (10.4049/jimmunol.168.9.4391)
- Savage, P. et al., 2002. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer 98 (4), pp.561-566. (10.1002/ijc.10219)
- Savage, P. et al., 2002. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. British Journal of Cancer 86 (8), pp.1336-1342. (10.1038/sj.bjc.6600223)
- Evans, M. et al. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. The Journal of Immunology 167 (9), pp.5420-5428.
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19 (17-19), pp.2549-2556. (10.1016/S0264-410X(00)00488-6)
- Lawson, T. et al. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. International Immunology 13 (11), pp.1383-1390. (10.1093/intimm/13.11.1383)
- Lawson, T. et al. 2001. Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. International Immunology 13 (11), pp.1373-1381. (10.1093/intimm/13.11.1373)
- Man, S. T. and Fiander, A. N. 2001. Immunology of human papillomavirus infection in lower genital tract neoplasia [review]. Best Practice & Research Clinical Obstetrics & Gynaecology 15 (5), pp.701-714. (10.1053/beog.2001.0215)
- Youde, S. J. et al. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Research 60 (2), pp.365-371.
- Nimako, M. et al., 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Research 57 (21), pp.4855-4861.
- Fiander, A. N. et al. 1997. Therapeutic vaccines for cervical cancer: concept and clinical results. Biodrugs -Auckland- 8 (5), pp.331-338. (10.2165/00063030-199708050-00001)
- Borysiewicz, L. K. et al., 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. The Lancet 347 (9014), pp.1523-1527. (10.1016/s0140-6736(96)90674-1)
- Borysiewicz, L. K. et al., 1995. Development and initial clinical studies of TA-HPV in cervical cancer. European Journal of Cancer 31 (supp 3), pp.17-17. (10.1016/0959-8049(95)99882-z)
Ymchwil
Roedd fy ymchwil yn canolbwyntio ar rôl y system imiwnedd mewn canser, yn enwedig ceisio datblygu ffyrdd newydd o drin canser neu i fonitro statws y system imiwnedd i adnabod cleifion prognosis gwael. Datblygodd fy labordy ddulliau i ganfod, ynysu a thyfu celloedd T canser penodol a defnyddiodd y rhain i astudio samplau cleifion (lewcemia lymffocytig cronig).
Addysgu
Roeddwn i'n arweinydd addysgu ar gyfer yr Is-adran Canser a Geneteg, gan gysylltu â C4ME a darparu cymorth ar gyfer gweithgareddau addysgu sy'n gysylltiedig ag addysgu myfyrwyr meddygol UG. Roeddwn i'n arfer darlithio ac asesu cwrs ar gyfer y modiwlau Imiwnoleg Uwch (ME3045) ac Imiwnopatholeg ac Imiwnotherapi (ME3046).
Roeddwn i'n diwtor personol i 35 o fyfyrwyr meddygol (blynyddoedd 1-5) ac yn goruchwylio nifer o brosiectau SSC llenyddiaeth a labordy. Fe wnes i oruchwylio 27 o fyfyrwyr meddygol ar brosiectau ymgysylltu â'r gymuned (Gweithdai Iechyd Rhyngweithiol ar gyfer Ysgolion Cynradd Cymru).
Fe wnes i gyfweld â myfyrwyr ysgol feddygol ymgeiswyr (MMIs).
Bywgraffiad
Trosolwg o'r Gyrfa
- 2012-2024: Darllenydd, Is-adran Canser a Geneteg, Ysgol Feddygaeth, Prifysgol Caerdydd
- 2002-2012: Uwch Ddarlithydd, Heintiau ac Imiwnedd, Ysgol Feddygaeth, Prifysgol Caerdydd
- 1995-2003: Cymrawd Ymchwil Prifysgol y Gymdeithas Frenhinol, Adran Feddygaeth, Coleg Meddygaeth Prifysgol Cymru
- 1994-1995: Cymrawd Ymchwil Ôl-ddoethurol, Adran Feddygaeth, Coleg Meddygaeth Prifysgol Cymru
- 1990-1994: Cymrawd Ymchwil Ôl-ddoethurol, Adran Microbioleg, Prifysgol Virginia, UDA
Aelodaethau proffesiynol
- Aelod o Gymdeithas Imiwnoleg Prydain
Meysydd goruchwyliaeth
Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PhD yn y meysydd canlynol:
- Canser Imiwnoleg , yn enwedig canser y prostad
- Imiwnotherapi
- Antigenau tiwmor newydd
- Brechlynnau canser therapiwtig
- Goresgyn imiwnedd sy'n gysylltiedig â chanser
- Celloedd T fel biofarcwyr ar gyfer dilyniant clefyd a/neu ymateb i driniaeth
Ymgysylltu
Rwyf wedi bod yn weithgar mewn sawl agwedd ar ymgysylltu â'r cyhoedd:
- Gweithdai Iechyd Rhyngweithiol. Mae'r rhain wedi cael eu rhedeg gan fyfyrwyr meddygol fel rhan o'u prosiectau SSC 3ydd neu 4edd flwyddyn. Mae'r myfyrwyr yn ymweld ag ysgolion cynradd Cymru i ddysgu plant (9-11 oed) am y corff dynol a byw'n iach. Mae'r gweithdai yn cynnwys gweithgareddau, arddangosiadau a chwisiau "ymarferol" sydd wedi'u cynllunio i gadw sylw'r plant ac ot yn gwneud dysgu'n hwyl. Dechreuwyd y prosiect ar ei ffurf bresennol drwy gyllid gan brosiect Cyfnewid CIty Rhanbarth Prifysgol Caerdydd. Hyd yn hyn, ymwelwyd â 49 o ysgolion yng Nghaerdydd, Caerffili, Methyr Tudfull a Phontypridd.
- Gwyddoniaeth mewn Iechyd. Rwyf wedi cynnal myfyrwyr profiad gwaith (Blwyddyn 12) yn fy labordy.
- Cynyddu dealltwriaeth y cyhoedd o wyddoniaeth, yn enwedig imiwnoleg canser. Rwyf wedi rhoi sgyrsiau i godwyr arian elusen a grwpiau cymorth i gleifion.
Contact Details
Themâu ymchwil
Arbenigeddau
- Imiwnedd celloedd T
- Imiwnoleg tiwmor